Realbotix and 10Things Partner to Demonstrate Real-World Embodied AI at Humanoid Summit
LAS VEGAS — Realbotix Corp. (TSX-V: XBOT) (Frankfurt: 76M0.F) (OTC: XBOTF) (' Realbotix ' or the 'Company'), a leader in AI-powered humanoid robotics, is partnering with 10Things, an innovator in language-to-action AI, to showcase a joint demonstration at the Humanoid Summit in London, UK, on May 29–30.
Article content
Article content
The demonstration will feature a Realbotix humanoid integrated with 10Things' robotic arms, creating a responsive, voice-controlled system capable of performing tasks like operating a tablet, grasping objects, and handling tools – all in real time.
Article content
What Makes This Different:
Article content
Voice-Powered Control: Users can speak naturally to the robot, which then carries out physical tasks, no apps or manual input required.
Real Functionality: The arms can complete practical, everyday actions like tidying a surface, picking up items, or navigating a touchscreen.
Support for Accessibility: This system is built with ease-of-use in mind, especially for elderly users or those with limited mobility.
Adapts Over Time: The robot learns user routines and preferences, becoming more helpful and personalized with each interaction.
Multi-User Smart: It recognizes different household members and manages tasks based on who's asking and what's needed.
Safety First: All actions are trained and tested in simulated environments before live deployment.
Article content
'This collaboration is about using robotics to improve daily living,' said Andrew Kiguel, CEO of Realbotix. 'By combining physical embodiment with responsive dialogue and task execution, we're showing how these systems can offer real support in the home. Our AI robots have mastered human social interaction. Combined with the ability to take verbal instructions to complete household tasks, will be a game changer for our humanoids.'
Article content
'Our first product focus will be a robotic platform designed for human interaction and safety, developed in partnership with Realbotix,' said Kimate Richards, CEO of 10Things. 'This collaboration will showcase a human-centered robotic solution. Realbotix's technology is built to make interactions with robots more natural and personal. As these platforms may involve private information and biometric data, safety and privacy are essential. At 10Things, we are building our core framework using the latest in generative technologies, with safety, reliability, privacy, and security as foundational pillars to ensure consumer trust and deliver truly human-first robotic experiences.'
Article content
Visit Realbotix and 10Things at the Humanoid Summit, May 29–30 in London, England, to see the demonstration in person.
Article content
About Realbotix
Realbotix designs and manufactures AI powered humanoid robots that improve human experiences through connection, companionship and intelligent interaction.
Article content
Manufactured in the United States, Realbotix specializes in realistic, customizable robots built for entertainment, customer service, and personal well-being. Our patented AI and robotics technologies enable lifelike expression, motion, and social engagement, making us a category leader in the rapidly evolving field of human-centric robotics.
Article content
Follow Aria, our humanoid robot, on Instagram and TikTok.
Article content
About 10Things
10Things is a robotics software startup that integrates a customer centric approach to building platforms and applications for the future. 10Things is based in the United States with support and talent development across major universities and communities. Alongside building a robust platform 10Things is partnering with urban development of youth especially minorities and girls. The diversity in talent when focused on consumer goods will ensure all voices contribute to the brand and products.
Article content
10Things will be launching their new website www.10Things.tech on May 26, 2025.
Article content
This news release includes certain forward-looking statements as well as management's objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as 'may', 'will', 'plan', 'expect', 'anticipate', 'estimate', 'intend' and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, as described in more detail in our securities filings available at www.sedarplus.ca. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Article content
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Salesforce vs. HubSpot: Which CRM Stock Is the Smarter Buy Now?
Salesforce, Inc. CRM and HubSpot, Inc. HUBS are two of the most recognized names in customer relationship management (CRM) software. Both are cloud-based platforms that help businesses attract, convert and retain customers. However, they serve different ends of the market. Salesforce is the dominant force among large enterprises, while HubSpot is making strong inroads with small and mid-sized businesses (SMBs). As investors search for sustainable winners in enterprise tech, a deeper look into each company's fundamentals, growth outlook and valuation helps determine which of these CRM stocks offers stronger long-term potential. Salesforce: CRM Giant but Slowing Growth Warrants Caution Salesforce continues to dominate the CRM market, outpacing rivals like Microsoft, Oracle and SAP. Over the years, Salesforce has built a strong and interconnected platform. The acquisition of Informatica, Zoomin and Own Company shows its intent to move beyond its position as a CRM software maker and become a broader enterprise software provider focused on artificial intelligence (AI), data and collaboration. AI is now central to Salesforce's growth plan. Since rolling out Einstein GPT in 2023, the company has embedded generative AI into its platform to help businesses automate processes, improve decisions and offer better customer experiences. As AI adoption rises across industries, Salesforce is well-placed to benefit from the same. Its latest innovation, Agentforce, reflects that momentum. Paired with its Data Cloud, Agentforce has already hit $100 million in annualized revenues just two quarters after launch. More than 4,000 customers are using it for various tasks in sales, service and marketing. Data Cloud is also expanding fast, with annual recurring revenues growing more than 120% year over year. Salesforce's broader strategy of bringing apps, data and AI agents under one umbrella gives it a strong edge. However, Salesforce's biggest challenge right now is slowing sales growth. For years, the company has delivered double-digit revenue increases. However, that pace has now cooled to single digits. In the first quarter of fiscal 2026, revenues rose just 7.7% from a year ago, and non-GAAP earnings per share (EPS) grew by only 5.7%. This slowdown reflects cautious enterprise spending amid economic uncertainty and geopolitical pressures. Analysts anticipate that this trend will persist, with mid-to-high single-digit revenue growth expected for fiscal 2026 and 2027. Non-GAAP EPS is expected to grow at a low double-digit rate for the two fiscals. HubSpot: A Fast-Moving Player in the CRM Market HubSpot has carved out a strong position by focusing on ease of use, affordability and a highly integrated platform tailored for smaller and mid-sized businesses. Its all-in-one offering for marketing, sales, customer service and content management is driving financial performance. In the first quarter of 2025, the company's revenues and non-GAAP EPS increased 15.7% and 5.9%, respectively, on a year-over-year basis. HubSpot is also investing heavily in AI features, workflow automation and advanced reporting to appeal to larger mid-market customers. This strategic positioning gives HubSpot a lot of room to expand, especially as more SMBs digitize their sales and customer operations. Additionally, HubSpot's App Marketplace offers a customer-centric solution by making it simple for companies to find and seamlessly connect and integrate solutions to grow their businesses. As companies prioritize a digital-first approach, it is likely to create more opportunities for developers to build new integrations that support every stage of the customer journey. Analysts' estimates for the top and bottom lines suggest that HubSpot is likely to grow at a faster pace than Salesforce. The Zacks Consensus Estimate suggests mid-teen percentage growth for 2025 and 2026 revenues. Non-GAAP EPS is forecasted to rise in the mid-teen percentage range for 2025 and in the low 20s for 2026. HUBS' Premium Price: Worth Paying for the Growth? On the valuation front, HubSpot trades at 8.75 times forward sales compared to 5.84 times for Salesforce. While HubSpot looks more expensive, its higher growth momentum justifies the premium. Salesforce's lower valuation reflects its risks, including slowing sales growth and macroeconomic headwinds. Conclusion: HUBS Is the Better Pick Right Now Both Salesforce and HubSpot are strong companies with good business models, but they are at different points in their growth paths. Salesforce is more mature and is facing growth challenges, while HubSpot continues to grow at a steady pace. For long-term investors who want consistent performance, HubSpot looks like the smarter investment choice today, even at a higher valuation. Currently, HubSpot sports a Zacks Rank #1 (Strong Buy), making the stock a must-pick compared to Salesforce, which has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank stocks here. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Salesforce Inc. (CRM): Free Stock Analysis Report HubSpot, Inc. (HUBS): Free Stock Analysis Report
Cision Canada
an hour ago
- Cision Canada
From Diagnosis to Surgery: How AI Tech Is Quietly Reshaping Healthcare Profits
VANCOUVER, BC, July 22, 2025 /CNW/ -- USA News Group News Commentary – The AI revolution in healthcare is fully underway, with the potential to save lives and money, but there's still more to come. Healthcare startups are already figuring out how to implement AI to multiply their patients, and chase profits, to the benefit of investors. More Americans than ever are utilizing AI to diagnose their health issues, as the adoption of AI tools is becoming the norm among medical professionals. Now the developers of these game-changing technologies are overcoming regulatory barriers and moving closer to implementation of their solutions in the real world. Among the players that are moving closer to major milestones include Avant Technologies, Inc. (OTCQB: AVAI), Agenus Inc. (NASDAQ: AGEN), Clover Health Investments, Corp. (NASDAQ: CLOV), Zimmer Biomet Holdings, Inc. (NYSE: ZBH), and Monogram Technologies Inc. (NASDAQ: MGRM). Currently, the AI in healthcare sector projected to surpass $110 billion by 2030. However, according to Accenture, artificial intelligence could unlock an additional $461 billion in value across healthcare by 2035—on top of a sector already projected to surpass $2.26 trillion. Avant Technologies, Inc. (OTCQB: AVAI) and joint-venture partner Ainnova Tech are continuing to raise visibility for their AI-powered diagnostic platform, with Ainnova CEO Vinicio Vargas recently featured as a speaker at Roche's"Macular Spectacular" Ophthalmology Conference in Cartagena, Colombia. The event brought together leading voices in visual health from across Latin America, with discussions focused on advancing patient outcomes through AI innovation. Vargas, who also sits on the board of Ai-nova Acquisition Corp. (AAC), presented Vision AI as a transformative tool to expand access to early diabetic retinopathy screening and reduce preventable blindness throughout the region. Vargas also highlighted a Q4 2024 alliance with Roche and prepaid‑health‑plan provider Salud 360 that is piloting Vision AI among high‑risk diabetic patients; if successful, the program will be rolled out in the United States, Canada, and Europe through Ai ‑ nova Acquisition Corp. (AAC), which holds worldwide rights to Ainnova's technology portfolio . This momentum builds on a recent regulatory breakthrough in the U.S. market. Avant and Ainnova recently completed a key pre-submission meeting with the FDA for Vision AI, the companies' flagship diagnostic platform for diabetic retinopathy and other retinal diseases. "We're truly excited about this next phase," said Vinicio Vargas, CEO at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio. "We're getting ready to begin data collection across primary care clinics in the U.S. with a study that is simple, yet rigorous—comparing our AI-based retinal screening to the readings of three retinologists. The July 15 meeting marked a critical step toward securing 510(k) clearance for Vision AI. The FDA session offered clear feedback on study design, site selection, and execution strategy—enabling Ainnova and its clinical trial partner, Fortrea, to finalize preparations for U.S.-based trials. "This milestone not only brings us closer to validating our platform in the world's largest healthcare market, but it also paves the way for the upcoming approval of our new automated retinal camera," added Vargas. "We believe will [it] be a game changer—making diabetic retinal screenings faster, more accessible, and available from virtually any point of care." While regulatory efforts advance in the U.S., the company has already launched a groundbreaking chronic care model across Latin America. The program, now live through Grupo Dökka's Fischel and La Bomba pharmacy chains, offers free, walk-in retinal risk assessments—delivering real-time AI results and connecting at-risk patients directly with clinics and specialists. Over 30% of diabetics develop diabetic retinopathy, a leading cause of preventable blindness. Vision AI offers early, low-cost screening without the need for an ophthalmologist onsite. The model has gained support from pharmacies, insurers, and pharmaceutical partners—demonstrating real traction across the healthcare value chain. Avant' s role in these efforts continues to grow. Through Ai-nova Acquisition Corp., which it co-founded and structured, Avant maintains global licensing rights to Ainnova's platform and stands to benefit from both U.S. and international commercialization. The Latin American pilot programs are already generating momentum, with U.S. trials positioned to unlock a vastly larger market. The company is also preparing a standalone venture to house a potential therapeutic candidate for diabetes—bringing leadership, data, and IP into one streamlined structure for diagnostics and treatment alike. Looking ahead, Vision AI could serve as a frontline tool for broader disease detection. Ainnova's future roadmap includes a cloud-connected retinal camera for rural clinics and new modules aimed at identifying Alzheimer's, cardiovascular conditions, and other chronic diseases through retinal or blood biomarkers. A structural simplification may be on the horizon as well. A previously announced non-binding LOI remains active for Avant to acquire 100% of Ainnova Tech —potentially consolidating all IP, leadership, and commercial rights under one public entity. Such a move would give investors pure-play exposure to this fast-evolving tech stack, while deepening operational alignment between the firms. Agenus Inc. (NASDAQ: AGEN) has partnered with AI biotech firm Noetik to develop predictive biomarkers for its cancer immunotherapy combo BOT/BAL. "At Agenus, we are committed to transforming cancer care through scientific innovation and next-generation immunotherapies," said Dr. Garo Armen, Chairman and CEO of Agenus. "This collaboration with Noetik enables us to harness cutting-edge AI to better understand patient biology and tailor treatments more precisely." By using Noetik's advanced "virtual cell" models trained on massive tumor datasets, the collaboration aims to identify which patients are most likely to benefit from treatment. This could improve clinical trial outcomes and accelerate personalized cancer care using AI-driven insights Clover Health Investments, Corp. (NASDAQ: CLOV) recently launched a new pharmacy pilot program across New Jersey in partnership with IPC's iCare+ network. The initiative enables local pharmacies to use AI tools and real-time data to help seniors manage medications and reduce hospital visits. "This is more than a new program—it's a new model for how we support our New Jersey members," said Jamie Reynoso, CEO of Medicare Advantage at Clover Health. "By working with the pharmacists who are already embedded in our communities, we can deliver better care, deliver amazing customer experiences and support the independent businesses that keep New Jersey strong." It's part of Clover's strategy to deliver more personal, community-based healthcare while supporting independent pharmacies Zimmer Biomet Holdings, Inc. (NYSE: ZBH) has entered a definitive agreement to acquire Monogram Technologies Inc. (NASDAQ: MGRM) for approximately US$177 million in cash, with additional milestone-based payments up to US$12.37 per share. " Monogram's technology is a major leap forward, demonstrating our commitment to becoming the boldest and broadest innovator in surgical robotics and navigation," said Ivan Tornos, Chairman, President and CEO of Zimmer Biomet. "Upon closing, our customer-centric portfolio will consist of the most comprehensive and flexible technology ecosystem to support the varying preferences of a vast array of surgeons – now and into the future. With Monogram's proprietary technology, Zimmer Biomet has the potential to become the first company to deliver fully autonomous capabilities and redefine both the standard of care and the future of orthopedic surgery." The acquisition adds Monogram's semi- and fully autonomous orthopedic robotics to Zimmer Biomet's ROSA® platform, aiming to create the most comprehensive robotics suite in the orthopedic space. Monogram's FDA-cleared knee arthroplasty robot is expected to commercialize in 2027, with a fully autonomous version in development. "Since our inception, we have been singularly focused on advancing orthopedic robotics with technology designed to safely, efficiently and accurately support surgeons with total knee arthroplasty," said Benjamin Sexson, CEO of Monogram. "We are thrilled by the opportunity to add our technology to Zimmer Biomet's leading portfolio of surgical robotics, navigation solutions and trusted implants and to benefit from their deep industry expertise and global scale." Zimmer Biomet expects the deal to be accretive by 2028, supporting long-term growth in the high-demand surgical robotics market. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Globe and Mail
an hour ago
- Globe and Mail
Regulatory Green Lights Are Powering the Next Phase of the AI Health Boom
Issued on behalf of Avant Technologies Inc. VANCOUVER – News Commentary – Artificial intelligence is rapidly transforming the healthcare landscape, unlocking new possibilities for early detection, patient care, and operational efficiency. Startups across the sector are deploying AI-driven tools to expand patient access, streamline workflows, and generate scalable revenue models that appeal to forward-looking investors. With usage accelerating among both patients and providers, AI-powered diagnostics and treatment platforms are quickly becoming standard practice. As regulatory hurdles begin to fall, several innovators are approaching key commercial inflection points—including Avant Technologies, Inc. (OTCQB: AVAI), AI Inc. (CSE: TRUE) (OTCQB: TREIF), Schrödinger, Inc. (NASDAQ: SDGR), Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX), and Rallybio Corporation (NASDAQ: RLYB). The AI healthcare market is expected to top US$110 billion by 2030, but Accenture suggests the upside could be far greater—projecting over US$461 billion in additional value creation by 2035, layered on top of a sector already forecasted to exceed US$2.26 trillion. Avant Technologies, Inc. (OTCQB: AVAI) and joint-venture partner Ainnova Tech are continuing to raise visibility for their AI-powered diagnostic platform, with Ainnova CEO Vinicio Vargas recently featured as a speaker at Roche's 'Macular Spectacular' Ophthalmology Conference in Cartagena, Colombia. The event brought together leading voices in visual health from across Latin America, with discussions focused on advancing patient outcomes through AI innovation. Vargas, who also sits on the board of Ai-nova Acquisition Corp. (AAC), presented Vision AI as a transformative tool to expand access to early diabetic retinopathy screening and reduce preventable blindness throughout the region. Vargas also highlighted a Q4 2024 alliance with Roche and prepaid‑health‑plan provider Salud 360 that is piloting Vision AI among high‑risk diabetic patients; if successful, the program will be rolled out in the United States, Canada, and Europe through Ai ‑ nova Acquisition Corp. (AAC), which holds worldwide rights to Ainnova's technology portfolio . This momentum builds on a recent regulatory breakthrough in the U.S. market. Avant and Ainnova recently completed a key pre-submission meeting with the FDA for Vision AI, the companies' flagship diagnostic platform for diabetic retinopathy and other retinal diseases. 'We're truly excited about this next phase,' said Vinicio Vargas, CEO at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio. 'We're getting ready to begin data collection across primary care clinics in the U.S. with a study that is simple, yet rigorous—comparing our AI-based retinal screening to the readings of three retinologists. The July 15 meeting marked a critical step toward securing 510(k) clearance for Vision AI. The FDA session offered clear feedback on study design, site selection, and execution strategy—enabling Ainnova and its clinical trial partner, Fortrea, to finalize preparations for U.S.-based trials. 'This milestone not only brings us closer to validating our platform in the world's largest healthcare market, but it also paves the way for the upcoming approval of our new automated retinal camera,' added Vargas. 'We believe will [it] be a game changer—making diabetic retinal screenings faster, more accessible, and available from virtually any point of care.' While regulatory efforts advance in the U.S., the company has already launched a groundbreaking chronic care model across Latin America. The program, now live through Grupo Dökka's Fischel and La Bomba pharmacy chains, offers free, walk-in retinal risk assessments—delivering real-time AI results and connecting at-risk patients directly with clinics and specialists. Over 30% of diabetics develop diabetic retinopathy, a leading cause of preventable blindness. Vision AI offers early, low-cost screening without the need for an ophthalmologist onsite. The model has gained support from pharmacies, insurers, and pharmaceutical partners—demonstrating real traction across the healthcare value chain. Avant' s role in these efforts continues to grow. Through Ai-nova Acquisition Corp., which it co-founded and structured, Avant maintains global licensing rights to Ainnova's platform and stands to benefit from both U.S. and international commercialization. The Latin American pilot programs are already generating momentum, with U.S. trials positioned to unlock a vastly larger market. The company is also preparing a standalone venture to house a potential therapeutic candidate for diabetes—bringing leadership, data, and IP into one streamlined structure for diagnostics and treatment alike. Looking ahead, Vision AI could serve as a frontline tool for broader disease detection. Ainnova's future roadmap includes a cloud-connected retinal camera for rural clinics and new modules aimed at identifying Alzheimer's, cardiovascular conditions, and other chronic diseases through retinal or blood biomarkers. A structural simplification may be on the horizon as well. A previously announced non-binding LOI remains active for Avant to acquire 100% of Ainnova Tech —potentially consolidating all IP, leadership, and commercial rights under one public entity. Such a move would give investors pure-play exposure to this fast-evolving tech stack, while deepening operational alignment between the firms. AI Inc. (CSE: TRUE) (OTCQB: TREIF) and its digital health platform Rocket Doctor have diverted thousands of low-acuity patients from overwhelmed Canadian emergency rooms using smart triage, AI tools, and virtual MD visits. 'We see so many patients in our rural, remote and even urban communities going to ED, often when they recognize that they could be seen outside the hospital.' Said Dr. William Cherniak, CEO of Rocket Doctor. 'There has been a lot of good content from the Canadian Association of Emergency Physicians (CAEP) to recognize that we need to support patients to access healthcare where they see most appropriate. We often see patients choose an ED with low-acuity issues simply because of a lack of access to family doctors, or other accessible out-patient choices.' Their program at Georgian Bay General Hospital alone saved an estimated CA$1.4 million and resolved 97.5% of patient cases virtually. With over 12,000 recent visits in Alberta and continued provincial expansion, the AI-powered system is proving its value at scale Schrödinger, Inc. (NASDAQ: SDGR) received FDA Fast Track designation for its AI-discovered MALT1 inhibitor, SGR-1505, targeting relapsed/refractory Waldenström macroglobulinemia. "We are excited to receive Fast Track designation for SGR-1505, which underscores the significant need in patients with Waldenström macroglobulinemia," said Karen Akinsanya, Ph.D., president, head of therapeutics R&D and chief strategy officer, partnerships at Schrödinger. "Despite the continued therapeutic advances in the treatment of hematologic malignancies, treatment failure and disease progression due to BTK resistance remains a challenge for a growing number of patients. This unmet need represents an opportunity for novel mechanisms such as MALT1 as monotherapy and as part of new combination regimens." The drug candidate, developed using Schrödinger's proprietary computational platform, has shown promising early results across several B-cell malignancies. This milestone highlights the growing role of AI-driven molecular discovery in accelerating cancer drug development. Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) has acquired full rights to REV102, a potential first-in-class oral therapy for hypophosphatasia (HPP), a rare genetic bone disorder with limited treatment options. Developed in collaboration with Rallybio Corporation (NASDAQ: RLYB), REV102 targets the ENPP1 enzyme and is being positioned as a convenient, non-immunogenic alternative to costly injectable enzyme replacement therapies. 'We extend our sincere thanks to Rallybio for their invaluable partnership in advancing this program to its current stage,' said David Hallett, Chief Scientific Officer of Recursion. 'Having full ownership of this important program allows Recursion to accelerate the development of the first potential oral disease-modifying treatment to HPP patients, who currently face significant challenges with limited access to existing therapies. While this is a preclinical asset that will require further study, we look forward to leveraging the full power of the Recursion OS to gain even deeper insights and accelerate delivery of the potential treatment.' Recursion used its proprietary AI-driven Recursion OS to design and optimize the drug, which has shown promising preclinical results and is expected to enter Phase 1 trials in 2026. 'The Rallybio team has long been committed to targeting ENPP1 to address a significant unmet need in patients with HPP,' said Stephen Uden, M.D., CEO of Rallybio. 'By combining Rallybio's expertise in HPP preclinical and translational research with Recursion's integrated AI/experimental platform, we transformed this concept into the first potential oral disease-modifying treatment for HPP. We look forward to the advancement of REV102 through key milestones and, ultimately, to the delivery of this important treatment to patients in need.' Under the deal, Rallybio will receive equity, milestones, and royalties as Recursion advances development. CONTACT: cs@ (250) 999-4849 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. is a wholly-owned subsidiary of Media Corp. ('BAY') BAY has been not been paid a fee for Avant Technologies Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Avant Technologies Inc. which were purchased in the open market. BAY and all of it's respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
